Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Socinski Says Immunotherapy, Targeted Therapy Have Altered Outlook in NSCLC

January 29th 2019

Mark A. Socinski, MD, provides an overview of treatment advances in the lung cancer landscape, and highlights where much-needed work still remains.

Expert Stresses Significance of Durvalumab Success in Stage III NSCLC

January 28th 2019

Findings from the PACIFIC trial have made a significant impact on the treatment of patients with unresectable stage III non–small cell lung cancer, especially in light of the history of treatment options in this setting.

Dr. Decker on Current Role of Radiation in NSCLC

January 28th 2019

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses the current role of radiation therapy in the treatment of patients with non–small cell lung cancer.

Brahmer Provides a Glimpse of Future Immunotherapeutics in NSCLC

January 28th 2019

Despite the rapidly expanding therapeutic options available in immunotherapy for patients with non-small cell lung cancer, there are still a number of drawbacks to treatment, explaining why not all patients respond to current treatment options.

Dr. Jahanzeb on Eligibility Criteria for Immunotherapy Trials in NSCLC

January 28th 2019

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the eligibility criteria for immunotherapy trials in non–small cell lung cancer.

Targeted Agents Show Promise Against Emerging Oncogenic Drivers in NSCLC

January 28th 2019

Data on many new treatment options have come forward over the past year highlighting the potential to treat more emerging oncogenic drivers impacting smaller subsets of patients with non–small cell lung cancer.

Surgery Maintains Role in Rapidly Advancing Lung Cancer Treatment Paradigm

January 28th 2019

Eric Vallieres, MD, highlights the technological advances of lung cancer surgery and how this impacts the outlook for patients who are candidates for it.

Dr. Wakelee Discusses Current State of Treatment in NSCLC

January 27th 2019

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses the current state of treatment in patients with non–small cell lung cancer.

Dr. Goldberg Discusses Treatment Approaches for Mesothelioma

January 27th 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses traditional and emerging treatment approaches for patients with mesothelioma.

Treatment Options Expand for ROS1, BRAF, and NTRK Alterations in NSCLC

January 27th 2019

A growing focus on smaller oncogenic drivers in lung cancer has opened up new treatment options and many potential drugs in development for patients with less common alterations.

EGFR-Targeted Activity Helps Differentiation Between TKIs in NSCLC

January 27th 2019

The treatment paradigm for EGFR-mutant non–small cell lung cancer has grown significantly with many EGFR TKIs now available to treat patients with this disease.

Lilenbaum Examines EGFR+ NSCLC Advancements and Potential Role of Immunotherapy

January 27th 2019

Rogerio Lilenbaum, MD, highlights the current treatment approaches for patients with EGFR-positive non–small cell lung cancer and shed light on the potential for immunotherapy in the space.

Dr. Brahmer on Managing Immune-Related AEs in Lung Cancer

January 26th 2019

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing immune-related adverse events in lung cancer.

Dr. Garon on Potential for Immunotherapy in EGFR+ NSCLC

January 26th 2019

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.

Dr. Kris Discusses Role of Antiangiogenesis in Lung Cancer

January 25th 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the role of antiangiogenesis in the treatment of patients with lung cancer.

BMS Withdraws Application for Nivolumab/Ipilimumab in TMB-High NSCLC

January 24th 2019

Bristol-Myers Squibb has withdrawn its supplemental biologics license application for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

Evidence Grows for Earlier Immunotherapy in NSCLC

January 24th 2019

Clinical trial evidence is building for moving checkpoint blockade immunotherapy forward in the treatment timeline for non–small cell lung cancer, but improving patient selection for these therapies remains a key challenge.

Dr. Camidge Discusses Treatment of Patients With ALK+ NSCLC

January 24th 2019

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment strategies for patients with ALK-mutated non–small cell lung cancer.

Recent Progress in Squamous NSCLC and SCLC Moves Needle Forward

January 23rd 2019

Janakiraman Subramanian, MD, discusses ongoing advances and remaining challenges in the field of lung cancer.

Dr. Kujtan on Patient Preferences in the Treatment of NSCLC

January 23rd 2019

Lara Kujtan, MD, assistant professor at the University of Missouri–Kansas City School of Medicine, discusses the importance of patient preferences in the treatment of oncogene-driven non-small cell lung cancer (NSCLC).